Introduction {#S0001}
============

Buruli ulcer (BU) is a cutaneous Neglected Tropical Disease (NTD) caused by *Mycobacterium ulcerans* \[[@CIT0001]--[@CIT0003]\]. It is the third most frequent mycobacterial infection after tuberculosis and leprosy \[[@CIT0001], [@CIT0002]\]. A plasmid of *M. ulcerans* encodes the production of mycolactone \[[@CIT0003]\], an immunomodulatory Macrolide toxin that causes tissue necrosis \[[@CIT0004]\].

Many antimycobacterial agents show activity against *M. ulcerans* in vitro, and experiments in animals, such as the mouse footpad model, show that Streptomycin in combination with Rifampicin is highly bactericidal \[[@CIT0005], [@CIT0006]\]. In a pilot study sponsored by WHO, 31 patients clinically diagnosed with pre-ulcerative *M. ulcerans* infection were treated with Streptomycin and Rifampicin for 0, 2, 4, 8, or 12 weeks \[[@CIT0007]\]. In 2000, the WHO Advisory Group on Buruli ulcer recommended a study to examine the possible benefit of antibiotic treatment in human subjects \[[@CIT0007]\]. With very convincing results obtained in Ghana and Benin the WHO has published a guide on the establishing antibiotics in the treatment of BU.

On the basis of these findings, preliminary guidelines were issued by the WHO recommending Streptomycin together with Rifampicin as a standard treatment for *M. ulcerans* infection, \[[@CIT0008]\] with or without additional surgical debridement or skin grafting. Synthesizing evidences on the efficacy of antibiotic in the management of BU can help to better define their roles, identify weaknesses and inform clinicians on relevant measures than can be used to control BU. We therefore conducted a systematic review to summarize the evidence of the clinical efficacy of Rifampicin and Streptomycin on the control of BU.

Objectives {#S20002}
----------

The aim of this study is to assess the clinical efficacy of Rifampicin-Streptomycin given for 8 weeks for the treatment of early *M. ulcerans* infection. The specific objectives of this study are to: rReview the current state of knowledge on the activities of Rifampicin and Streptomycin combined against *M. ulcerans* infection; to determine which oral antibiotics is more effective for managing BU with or without surgical excision.

Methods {#S0003}
=======

Search strategy {#S20004}
---------------

We searched the following electronic databases from January 2005 to July 2012: Medline, EMBASE (Excerpta Medica Database), the Cochrane Library, Google Scholar, CINAHL (Cumulative Index to Nursing and Allied Health Literature), WHOLIS (World Health Organization Library Database), LILACS (Latin American and Caribbean Literature on Health Sciences) and contacted experts in the field. There were no restrictions to language or publication status. Our search was limited to the last seven years, as they correspond to the period of where the WHO validated antibiotic treatment of BU \[[@CIT0008]\]. We used the following terms in our search: *clinical efficacy, Rifampicin and Streptomycin, antibiotic treatment, Buruli ulcer, Mycobacterium ulcerans, and outcome*.

**Study design:** All study designs were eligible for inclusion provided they were on antibiotic treatment.

**Study participants:** Owing to the wide range of functions that fall under the umbrella term "clinical efficacy" we designed a definition of our own. For this review, we defined antibiotic treatment as individuals trained in the particular role of delivering curative or preventive care in the management of BU.

**Types of interventions:** We included interventions if the description was adequate for us to establish that it was an antibiotic treatment of BU. Where such details were unclear, we contacted the study authors, whenever possible, for more information.

**Outcomes:** Any of the following outcomes were sought:Type of treatmentClinical efficacy of Rifampicin and StreptomycinSide effectsThe role of the antibiotic treatment in the efficacy of surgery

**Data extraction and management:** Critical appraisal of all identified citations was done independently by two authors (VCT and CNT) to establish the possible relevance of the articles for inclusion in the review. Studies were reviewed for relevance based on types of participants, interventions (management of BU), and outcome measures. We retrieved full text copies of the articles identified as potentially relevant by either one or both review authors. Where appropriate, we contacted study authors for further information and clarification. Disagreements were resolved by consensus or by arbitration of a third review author (MZV). Data are reported in a narrative manner.

**Assessment of quality in included studies:** The included studies were not scored for quality.

Current status of knowledge {#S0005}
===========================

Our searches retrieved 115 studies, of which 09 are included in the review ([Figure 1](#F0001){ref-type="fig"}, [Table 1](#T0001){ref-type="table"}).

![PRISMA flow diagram](PAMJ-15-155-g001){#F0001}

###### 

Profile of different studies on the Buruli ulcer treatment in the world

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
          Reference                               Type of study   Country     Type of antibiotic association   Number of weeks of treatment                       Route of administration   Number of patients
  ------- --------------------------------------- --------------- ----------- -------------------------------- -------------------------------------------------- ------------------------- --------------------
  **1**   Chauty et al., 2007 \[[@CIT0020]\]      Cohort study    Benin       Streptomycin-Rifampin            8 weeks                                            Injection                 224

  **2**   Chauty et al., 2011 \[[@CIT0013]\]      Cohort study    Benin       Streptomycin-Rifampin            8 weeks                                            Per os                    30

  **3**   Etuaful et al., 2005 \[[@CIT0007]\]     RCT             Ghana       Streptomycin-Rifampin            12 weeks and surgery was performed after 4 weeks   Injection and per os      Not\
                                                                                                                                                                                            reported

  **4**   Gordon et al., 2010 \[[@CIT0010]\]      RCT             Autralia    Streptomycin-Rifampin            between 4 and 8 weeks                              Per os                    04

  **5**   Kibadi et al, 2010 \[[@CIT0014]\]       Cohort study    DRC         Streptomycin-Rifampin            12 weeks and surgery was performed after 4 weeks   Injection                 92

  **6**   O\'Brien et al., 2012 \[[@CIT0011]\]    Cohort study    Australia   Streptomicin-Rifampicin          8 weeks                                            Per os                    133

  **7**   Nienhuis et al., 2010 \[[@CIT0009]\]    RCT             Ghana       Streptomicin-Rifampicin          8 weeks                                            Injection et per os       151

  **8**   Saka et al., 2012\                      Cohort study    Togo        Streptomicin-Rifampicine         8 weeks                                            Injection and per os      119
          \[[@CIT0012]\]                                                                                                                                                                    

  **9**   Agbenorku et al., 2007 \[[@CIT0016]\]   Cohort study    Ghana       Streptomicin-Rifampicin          8 weeks                                            Injection et per os       62
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study characteristics {#S20006}
---------------------

Nine studies including 3 Randomised Controlled Trials (RCTs) \[[@CIT0007], [@CIT0009], [@CIT0010]\] and 06 cohorts \[[@CIT0011]--[@CIT0014], [@CIT0016], [@CIT0020]\] met the inclusion criteria ([Figure 1](#F0001){ref-type="fig"}).

**The different combinations and mode of administration of antibiotics:** All nine studies evaluated the efficacy of combinationing Streptomycin-Rifampin in confirmed BU patients \[[@CIT0007], [@CIT0009]--[@CIT0014], [@CIT0016], [@CIT0020]\]. Three studies have evaluated the oral treatment \[[@CIT0010], [@CIT0011], [@CIT0013]\], 02 studies treatment injection \[[@CIT0014]--[@CIT0020]\] and 02 studies compared treatment with oral and one by injections of antibiotics \[[@CIT0007]--[@CIT0009]\].

**Antibiotic treatment associated with surgery:** The surgery was performed after an antibiotic treatment in three studies \[[@CIT0010], [@CIT0012], [@CIT0013]\]. Lesion size at baseline was the main factor associated with surgery. The duration of treatment ranged from 8 to 48 weeks depending on the severity and the mean duration of treatment was 8 weeks according to the WHO recommendations \[[@CIT0009], [@CIT0011]--[@CIT0013], [@CIT0016], [@CIT0020]\]. The average recovery period was 104 days (range, 30-212 days) \[[@CIT0013]\].

**Clinical efficacy of Rifampin-Streptomycin:** Oral chemotherapy alone obtained a curative rate of 50% \[[@CIT0013]\]. One participant developed an injection abscess and two others developed an abscess near the lesion, which was incised and drained \[[@CIT0009]\]. Saka and colleagues reported complications in 20 patients of which three were Amputated \[[@CIT0012]\].

Regarding the Polymerase Chain reaction (PCR) results after treatment Chauty and collaborators reported negative PCR results after treatment in 14 of the 27 samples analyzed, Etuaful and colleagues reported 07of the 21 samples negative by PCR, histopathology \[[@CIT0007]\], suggesting the persistence of mycobacterial material, as described by others.

The "dual" mode of treatment (surgery + chemotherapy) reduced hospital admission period from 90 to 40 days, that\'s to 44.2%. This would directly reduce the cost of treatment for the BU patients \[[@CIT0015]\].

The WHO has recommended the use of Rifampicin-Streptomycin (15 mg/kg once daily intramuscular streptomycin and 10 mg/kg Rifampin orally once daily) for the treatment of*Mycobacterium ulcerans* infection for a period of 8 weeks for first category lesions. Surgery comes in depending on the size of the lesion \[[@CIT0008]\].

Several authors have attempted to evaluate the effectiveness of different antibiotic therapies in the treatment of BU \[[@CIT0007], [@CIT0009], [@CIT0010], [@CIT0012], [@CIT0013], [@CIT0016]\] and most studies have evaluated the clinical efficacy of two different regimes of combination therapies \[[@CIT0007], [@CIT0009]--[@CIT0013], [@CIT0016], [@CIT0020]\].

After haven completed the antibiotic therapy, patients should be followed for at least 10 months (a total of 12 months from the start of treatment) to confirm healing, evaluate eventual complications and notice any relapses \[[@CIT0008]\].

All these results were obtained without toxic effect of antibiotics. The authors reported low treatment failure (below 40%) relative to the association Rifampin-Streptomycin \[[@CIT0009], [@CIT0010], [@CIT0012], [@CIT0013]\] and less than 20% Rifampin-Streptomycin associated with surgery \[[@CIT0007], [@CIT0012], [@CIT0013]\].

Chemotherapy by injection only managed to get a 47% cure and was particularly effective against ulcers less than 5 cm in diameter and no side effects were reported \[[@CIT0020]\]. Oral chemotherapy alone obtained a curative rate of 50% \[[@CIT0013]\].

This treatment happens to be of great help for the surgery because it sterilizes wounds, limits the size of the excisions and reduces the number of relapses. It turned out that the surgery was not required for early stages \[[@CIT0011]--[@CIT0013], [@CIT0015], [@CIT0016]\].

This treatment for early stages could therefore replace surgery and in severe cases, is an indispensable aid before surgery. Capable of being established at local health centres, this treatment could significantly reduce the cost of care and marginalization of patients. One participant developed an injection abscess and two others developed an abscess near the lesion which was incised and drained \[[@CIT0009]\]. Saka and colleagues reported complications in 20 patients of which three were Amputated \[[@CIT0012]\]. The average recovery period was 104 days (range, 30-212 days) \[[@CIT0013]\].

Regarding the PCR results after treatment Chauty and collaborators reported negative PCR results after treatment in 14 of the 27 samples analyzed \[[@CIT0013]\], Etuaful and colleagues reported 07 of the 21 samples negative by PCR, histopathology \[[@CIT0007]\], suggesting the persistence of mycobacterial material, as described by others.

*M. ulcerans* culture test were positive at the initial stage that is to say before the treatment and two weeks after treatment. They were then negative, indicating that this antibiotic combination may be useful to support the nodules and closets, the only type of damage covered by this study. Preliminary analysis of the test results sponsored by WHO (Study I) showed that treatment with Rifampicin and Streptomycin managed to make negative cultures in 4 to 12 weeks, but not after 2 weeks. During the period of observation before excision, most lesions decreased in size and we have reasons to believe that the clinical treatment by antibiotics alone is effective. Currently, data from extensive research suggests that there is no significant difference between oral antibiotic therapy and parenterally in the treatment of BU \[[@CIT0018], [@CIT0019]\]. However, the available data support the hypothesis that oral treatment of both antibiotics may be used as effectively as parenteral therapy in this particular group of children \[[@CIT0016], [@CIT0017]\]. Ji and colleagues showed that regimens combining Rifampicin or Moxifloxacin were as effective as Rifampicin-Streptomycin in mice \[[@CIT0018]\].

Studies by O\'Brien, Alffenaar, Almeida employees and collaborators showed that Rifampicin, Amikacin and streptomycin had a bactericidal activity on M. ulcerans \[[@CIT0011], [@CIT0016], [@CIT0023]\]. As Clarithromycin alone exhibited clear-cut bacteriostatic activity, an additive effect of the combination Rifapentine-Clarithromycin and even Rifampin-Clarithromycin was expected. Unfortunately the co-administration of a Rifamycin and Clarithromycin, both drugs given orally at doses equivalent to human doses was less effective than each Rifamycin alone in mice infected with *M. ulcerans* \[[@CIT0023]\].

These results have important implications for the treatment of patients with BU in developing countries, including the reduction of pain associated with needle complications and patient discomfort during treatment.

Conclusion {#S0007}
==========

These results confirmed that the daily administration of Rifampicin and Streptomycin is an effective treatment for *M. ulcerans* infection at an early stage. Subsequent systematic reviews should be conducted to determine whether antibiotics could heal injuries without resorting to surgery and to compare different treatment durations.
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